Marc L Schermerhorn1, Patric Liang2, Hanaa Dakour-Aridi3, Vikram S Kashyap4, Grace J Wang5, Brian W Nolan6, Jack L Cronenwett7, Jens Eldrup-Jorgensen6, Mahmoud B Malas8. 1. Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass. Electronic address: mscherm@bidmc.harvard.edu. 2. Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass. 3. Johns Hopkins Bayview Vascular and Endovascular Research Center, Baltimore, Md. 4. Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio. 5. Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pa. 6. Division of Vascular and Endovascular Therapy, Department of Surgery, Maine Medical Center, Portland, Me. 7. Section of Vascular Surgery and The Dartmouth Institute, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 8. Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego Health System, San Diego, Calif.
Abstract
OBJECTIVE: Transcarotid artery revascularization (TCAR) with flow reversal offers a less invasive option for carotid revascularization in high-risk patients and has the lowest reported overall stroke rate for any prospective trial of carotid artery stenting. However, outcome comparisons between TCAR and carotid endarterectomy (CEA) are needed to confirm the safety of TCAR outside of highly selected patients and providers. METHODS: We compared in-hospital outcomes of patients undergoing TCAR and CEA from January 2016 to March 2018 using the Society for Vascular Surgery Vascular Quality Initiative TCAR Surveillance Project registry and the Society for Vascular Surgery Vascular Quality Initiative CEA database, respectively. The primary outcome was a composite of in-hospital stroke and death. RESULTS: A total of 1182 patients underwent TCAR compared with 10,797 patients who underwent CEA. Patients undergoing TCAR were older (median age, 74 vs 71 years; P < .001) and more likely to be symptomatic (32% vs 27%; P < .001); they also had more medical comorbidities, including coronary artery disease (55% vs 28%; P < .001), chronic heart failure (20% vs 11%; P < .001), chronic obstructive pulmonary disease (29% vs 23%; P < .001), and chronic kidney disease (39% vs 34%; P = .001). On unadjusted analysis, TCAR had similar rates of in-hospital stroke/death (1.6% vs 1.4%; P = .33) and stroke/death/myocardial infarction (MI; 2.5% vs 1.9%; P = .16) compared with CEA. There was no difference in rates of stroke (1.4% vs 1.2%; P = .68), in-hospital death (0.3% vs 0.3%; P = .88), 30-day death (0.9% vs 0.4%; P = .06), or MI (1.1% vs 0.6%; P = .11). However, on average, TCAR procedures were 33 minutes shorter than CEA (78 ± 33 minutes vs 111 ± 43 minutes; P < .001). Patients undergoing TCAR were also less likely to incur cranial nerve injuries (0.6% vs 1.8%; P < .001) and less likely to have a postoperative length of stay >1 day (27% vs 30%; P = .046). On adjusted analysis, there was no difference in terms of stroke/death (odds ratio, 1.3; 95% confidence interval, 0.8-2.2; P = .28), stroke/death/MI (odds ratio, 1.4; 95% confidence interval, 0.9-2.1, P = .18), or the individual outcomes. CONCLUSIONS: Despite a substantially higher medical risk in patients undergoing TCAR, in-hospital stroke/death rates were similar between TCAR and CEA. Further comparative studies with larger samples sizes and longer follow-up will be needed to establish the role of TCAR in extracranial carotid disease management.
OBJECTIVE: Transcarotid artery revascularization (TCAR) with flow reversal offers a less invasive option for carotid revascularization in high-risk patients and has the lowest reported overall stroke rate for any prospective trial of carotid artery stenting. However, outcome comparisons between TCAR and carotid endarterectomy (CEA) are needed to confirm the safety of TCAR outside of highly selected patients and providers. METHODS: We compared in-hospital outcomes of patients undergoing TCAR and CEA from January 2016 to March 2018 using the Society for Vascular Surgery Vascular Quality Initiative TCAR Surveillance Project registry and the Society for Vascular Surgery Vascular Quality Initiative CEA database, respectively. The primary outcome was a composite of in-hospital stroke and death. RESULTS: A total of 1182 patients underwent TCAR compared with 10,797 patients who underwent CEA. Patients undergoing TCAR were older (median age, 74 vs 71 years; P < .001) and more likely to be symptomatic (32% vs 27%; P < .001); they also had more medical comorbidities, including coronary artery disease (55% vs 28%; P < .001), chronic heart failure (20% vs 11%; P < .001), chronic obstructive pulmonary disease (29% vs 23%; P < .001), and chronic kidney disease (39% vs 34%; P = .001). On unadjusted analysis, TCAR had similar rates of in-hospital stroke/death (1.6% vs 1.4%; P = .33) and stroke/death/myocardial infarction (MI; 2.5% vs 1.9%; P = .16) compared with CEA. There was no difference in rates of stroke (1.4% vs 1.2%; P = .68), in-hospital death (0.3% vs 0.3%; P = .88), 30-day death (0.9% vs 0.4%; P = .06), or MI (1.1% vs 0.6%; P = .11). However, on average, TCAR procedures were 33 minutes shorter than CEA (78 ± 33 minutes vs 111 ± 43 minutes; P < .001). Patients undergoing TCAR were also less likely to incur cranial nerve injuries (0.6% vs 1.8%; P < .001) and less likely to have a postoperative length of stay >1 day (27% vs 30%; P = .046). On adjusted analysis, there was no difference in terms of stroke/death (odds ratio, 1.3; 95% confidence interval, 0.8-2.2; P = .28), stroke/death/MI (odds ratio, 1.4; 95% confidence interval, 0.9-2.1, P = .18), or the individual outcomes. CONCLUSIONS: Despite a substantially higher medical risk in patients undergoing TCAR, in-hospital stroke/death rates were similar between TCAR and CEA. Further comparative studies with larger samples sizes and longer follow-up will be needed to establish the role of TCAR in extracranial carotid disease management.
Authors: Stefan Müller-Hülsbeck; Thomas Jahnke; Carsten Liess; Christoph Glass; Friedrich Paulsen; Jan Grimm; Martin Heller Journal: J Endovasc Ther Date: 2002-12 Impact factor: 3.487
Authors: Julia Glaser; David Kuwayama; David Stone; Andres Schanzer; Jens Eldrup-Jorgensen; Richard Powell; Andrew Stanley; Brian Nolan Journal: J Vasc Surg Date: 2014-05-24 Impact factor: 4.268
Authors: Rob G A Ackerstaff; Maarten J Suttorp; Jos C van den Berg; Tim Th C Overtoom; Jan A Vos; Egbert T Bal; Pieter Zanen Journal: J Vasc Surg Date: 2005-04 Impact factor: 4.268
Authors: Jörg Ederle; Joanna Dobson; Roland L Featherstone; Leo H Bonati; H Bart van der Worp; Gert J de Borst; T Hauw Lo; Peter Gaines; Paul J Dorman; Sumaira Macdonald; Philippe A Lyrer; Johanna M Hendriks; Charles McCollum; Paul J Nederkoorn; Martin M Brown Journal: Lancet Date: 2010-02-25 Impact factor: 79.321
Authors: Jay S Yadav; Mark H Wholey; Richard E Kuntz; Pierre Fayad; Barry T Katzen; Gregory J Mishkel; Tanvir K Bajwa; Patrick Whitlow; Neil E Strickman; Michael R Jaff; Jeffrey J Popma; David B Snead; Donald E Cutlip; Brian G Firth; Kenneth Ouriel Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Kenneth Rosenfield; Jon S Matsumura; Seemant Chaturvedi; Tom Riles; Gary M Ansel; D Chris Metzger; Lawrence Wechsler; Michael R Jaff; William Gray Journal: N Engl J Med Date: 2016-02-17 Impact factor: 91.245
Authors: Christopher J Kwolek; Michael R Jaff; J Ignacio Leal; L Nelson Hopkins; Rasesh M Shah; Todd M Hanover; Sumaira Macdonald; Richard P Cambria Journal: J Vasc Surg Date: 2015-11 Impact factor: 4.268
Authors: Marc L Schermerhorn; Patric Liang; Jens Eldrup-Jorgensen; Jack L Cronenwett; Brian W Nolan; Vikram S Kashyap; Grace J Wang; Raghu L Motaganahalli; Mahmoud B Malas Journal: JAMA Date: 2019-12-17 Impact factor: 56.272
Authors: Pavel Kibrik; David P Stonko; Ahmad Alsheekh; Courtenay Holscher; Devin Zarkowsky; Christopher J Abularrage; Caitlin W Hicks Journal: J Vasc Surg Date: 2022-05-25 Impact factor: 4.860
Authors: George Q Zhang; Sanuja Bose; David P Stonko; Christopher J Abularrage; Devin S Zarkowsky; Caitlin W Hicks Journal: J Vasc Surg Date: 2022-03-31 Impact factor: 4.860
Authors: Christina L Cui; Hanaa Dakour-Aridi; Jens Eldrup-Jorgensen; Marc L Schermerhorn; Jeffrey J Siracuse; Mahmoud B Malas Journal: J Vasc Surg Date: 2020-10-08 Impact factor: 4.268
Authors: Sarah E Deery; Courtenay M Holscher; Besma Nejim; Sara L Zettervall; Nathan J Aranson; Devin S Zarkowsky; Christopher J Abularrage; Caitlin W Hicks Journal: J Vasc Surg Date: 2021-09-22 Impact factor: 4.268
Authors: Hanaa Dakour-Aridi; Christina L Cui; Andrew Barleben; Marc L Schermerhorn; Jens Eldrup-Jorgensen; Mahmoud B Malas Journal: J Vasc Surg Date: 2020-11-27 Impact factor: 4.860